SC
SYRE icon

Stempoint Capital’s Spyre Therapeutics SYRE Stock Holding History

Stempoint Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.49M Sell
106,926
-60,680
-36% -$4.43M 1.64% 24
2026
Q1 		$8.45M Buy
167,606
+135,229
+418% +$5.1M 1.62% 21
2025
Q4 		$1.06M Buy
+32,377
New +$846K 0.18% 67
2025
Q2 		– Sell
-136,139
Closed -$2.2M – 79
2025
Q1 		$2.2M Buy
+136,139
New +$2.83M 0.7% 35
2024
Q3 		– Sell
-150,450
Closed -$3.54M – 67
2024
Q2 		$3.54M Buy
150,450
+88,197
+142% +$2.97M 1.04% 31
2024
Q1 		$2.36M Sell
62,253
-316,513
-84% -$9.17M 0.62% 35
2023
Q4 		$8.15M Buy
+378,766
New +$5.22M 2.17% 19

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Stempoint Capital's SYRE Position: Q2 2026 in Review

Stempoint Capital reduced its Spyre Therapeutics (SYRE) stake by 36% in Q2 2026, selling an estimated $4.43M and leaving 106,926 shares worth $9.49M. The position accounts for 1.64% of the portfolio, ranked #24.

Stempoint Capital first reported a position in SYRE in Q4 2023 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Stempoint Capital held 106,926 shares of Spyre Therapeutics worth $9.49M as of Q2 2026.
  • Stempoint Capital sold 60,680 Spyre Therapeutics shares in Q2 2026, an estimated $4.43M.
  • Spyre Therapeutics made up 1.64% of Stempoint Capital's portfolio in Q2 2026, its #24 holding.
  • Stempoint Capital first reported a position in Spyre Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.